The company
Natera, Inc.
NTRA · Nasdaq
Health CareDiagnostics & LabsLeading
NTRA stood above a rising 150-day average in 41 of the last 52 weekly readings, including each of the last 19 weeks. It is 47.2% above that average now. Diagnostics & Labs: 50% of its 44 stocks in an uptrend (+2 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 19 in a row
- Industry in uptrend
- 50% +2 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $686.4M
- Officials’ trades on record
- 13
- Institutions holding
- 793 (+78)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 41 of 52 weeks.
20 Apr – 19 Oct
Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
13 disclosed lines: House 6, Senate 1, executive 6; 4 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 17 Jul 2026filed 22 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 15 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 18 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 15 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 17 Mar 2026filed 14 May 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 19 Feb 2026filed 14 May 2026 |
| Josh Gottheimer House: U.S. House ClerkNJ05 | boughtjoint | $1k–$15k | 22 Sep 2025filed 15 Oct 2025 |
| Josh Gottheimer House: U.S. House ClerkNJ05 | boughtjoint | $1k–$15k | 22 Aug 2025filed 5 Sep 2025 |
| Josh Gottheimer House: U.S. House ClerkNJ05 | soldjoint | $1k–$15k | 22 Jul 2025filed 11 Aug 2025 |
| Josh Gottheimer House: U.S. House ClerkNJ05 | boughtjoint | $1k–$15k | 20 Nov 2024filed 5 Dec 2024 |
| Daniel S. Goldman House: U.S. House ClerkNY10 | sold | $1k–$15k | 10 Apr 2023filed 19 May 2023 |
| Daniel S. Goldman House: U.S. House ClerkNY10 | bought | $1k–$15k | 6 Mar 2023filed 17 Apr 2023 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months173
Buyers · sellers0 · 12
| Who | Did | Shares | Traded |
|---|---|---|---|
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 286at $388.32 | 15 Oct 2026filed 16 Oct 2026 |
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 714at $389.84 | 15 Oct 2026filed 16 Oct 2026 |
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 600at $390.21 | 15 Oct 2026filed 16 Oct 2026 |
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 300at $391.58 | 15 Oct 2026filed 16 Oct 2026 |
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 800at $393.47 | 15 Oct 2026filed 16 Oct 2026 |
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 300at $394.40 | 15 Oct 2026filed 16 Oct 2026 |
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 1,900at $396.30 | 15 Oct 2026filed 16 Oct 2026 |
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 1,100at $397.16 | 15 Oct 2026filed 16 Oct 2026 |
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 600at $398.09 | 15 Oct 2026filed 16 Oct 2026 |
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 793at $399.31 | 15 Oct 2026filed 16 Oct 2026 |
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 2,671at $400.31 | 15 Oct 2026filed 16 Oct 2026 |
| Matthew RabinowitzEXECUTIVE CHAIRMAN | sold | 5,974at $401.42 | 15 Oct 2026filed 16 Oct 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders793+78 on the quarter
New · exited153 · 76
Reported value$33.0B
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| JPMORGAN CHASE & COnew · filed 12 Aug 2026 | 12,865,346$3.5B | +12,865,346 |
| BlackRock, Inc.added · filed 7 Aug 2026 | 10,914,608$3.0B | +237,270+2.2% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 6,228,216$1.7B | +219,720+3.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 5,782,640$1.6B | +137,945+2.4% |
| FMR LLCadded · filed 13 Aug 2026 | 5,451,396$1.5B | +2,897,142+113.4% |
| WELLINGTON MANAGEMENT GROUP LLPreduced · filed 14 Aug 2026 | 4,040,738$1.1B | -727,855−15.3% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 3,655,618$992.3M | +238,146+7.0% |
| GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026 | 2,750,013$744.6M | -25,915−0.9% |
| FRANKLIN RESOURCES INCadded · filed 13 Aug 2026 | 2,725,903$739.9M | +240,578+9.7% |
| Castle Hook Partners LPadded · filed 14 Aug 2026 | 2,596,276$704.8M | +66,466+2.6% |
31 Mar 2023 – 30 Jun 2026
News
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology | wallstreetONLINEwallstreet-online.de · 19 Oct 2026Natera, TransCode Target Residual Colorectal Cancer With Trial Collaborationrttnews.com · 13 Oct 2026Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDArttnews.com · 9 Oct 2026Show Me The Money: Natera Delivers Over 120% Gain In Just About A Yearfinanznachrichten.de · 18 Sep 2026Jim Cramer Calls Natera (NTRA) "a Promising Story"yahoo.com · 9 Sep 2026
Everyone who traded it
Same industry
Government contracts
Awards2
Total$678K
Latest15 Oct 2026
From its SEC filings
Analyst forecasts
No analyst forecasts yet.